Drug Treatments

Summary:
10 therapeutic agents are in active clinical trials. Another 15 therapeutic agents are in planning stages. Currently the three (3) most likely drugs to be safe and effective are, for critically ill COVID-19 patients: (1) Remdesivir anti-viral drug by Gilead, and (2) Actemra/RoActemra (Tocilizumab) immunosuppressive drug by Roche, and for early stage SARS-CoV-2 infection: (3) Avigan (favipiravir) anti-viral drug by Fujifilm, Japan.
Published for educational purposes and social benefit, not for profit. Not a recommendation or endorsement. Always consult your doctor for medical advice.

July 2021

CELL & HOST MICROBE | SnapShot: SARS-CoV-2 antibodies

2021-07-17T08:35:03+00:00July 17th, 2021|

Monoclonal antibody therapies hold great promise for COVID-19; however, the recent emergence and spread of escape variants threaten to limit their value. Shown here are structural and linear representations of [...]

April 2021

November 2020

KAROLINSKA INSTITUTET | Baricitinib treatment linked to reduced mortality in COVID-19 patients | JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

2020-11-15T06:57:07+00:00November 15th, 2020|

JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality ABSTRACT. Using AI we identified baricitinib as possessing anti-viral and anti-cytokine efficacy. We now show [...]

October 2020

August 2020

July 2020